The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The BEST trial (E2804): A randomized phase II study of VEGF, RAF kinase, and mTOR combination targeted therapy (CTT) with bevacizumab (bev), sorafenib (sor), and temsirolimus (tem) in advanced renal cell carcinoma (RCC).
David F. McDermott
Consultant or Advisory Role - Genentech; Pfizer
Judith Manola
No relevant relationships to disclose
Michael Pins
No relevant relationships to disclose
Keith T. Flaherty
No relevant relationships to disclose
Michael B. Atkins
No relevant relationships to disclose
Janice P. Dutcher
Consultant or Advisory Role - Genentech; Pfizer
Honoraria - Bayer; Genentech; Pfizer
Daniel J. George
No relevant relationships to disclose
Kim Allyson Margolin
Consultant or Advisory Role - Genentech; GlaxoSmithKline
Research Funding - Bayer; Genentech; GlaxoSmithKline; Pfizer
Robert S. DiPaola
No relevant relationships to disclose